Superworth

Travere Therapeutics profit margin TVTX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.

Net margin, 12 months
−18.7%
Operating margin, 12 months
−20.5%
Net margin on a year earlier
+1.7 pts
Peer median
8.1%

Over the twelve months to Sep 30, 2026, Travere Therapeutics kept −18.7% of its revenue as net profit, with an operating margin of −20.5% and a gross margin of 98.5%.

The median for 10 large drugmakers of a similar size is 8.1%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−5.2%−12.8%97.9%
FY2024n/an/a96.7%
FY2023−76.7%n/a92.1%
FY2022n/an/an/a
FY2021−79.2%−71.1%97.0%
FY2020−85.4%−88.8%96.9%
FY2019−83.5%−78.3%97.0%
FY2018−62.5%−48.7%96.6%
FY2017−38.6%−34.7%97.7%
FY2016−35.9%−43.6%96.6%
FY2015n/a−50.8%97.8%
FY2014n/an/a98.0%
FY2013n/an/an/a
FY2012n/an/an/a
FY2012n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q3 FY26−18.7%+1.7 pts−20.5%
Q2 FY26−7.4%+43.3 pts−6.8%
Q1 FY26−4.0%+78.9 pts−10.6%
Q4 FY25−5.2%n/a−12.8%
Q3 FY25−20.3%n/a−20.9%
Q2 FY25−50.6%+31.5 pts−51.6%
Q1 FY25−82.9%n/a−83.1%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24−82.1%n/an/a
Q1 FY24n/an/an/a
Q4 FY23−76.7%n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

Where Travere Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Travere Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.